Currently HXL is ranked in last position of ASX pharmaceutical sector, $2.7m cash left by the end of this year, no debt, MC $2.7m LOL.
New major shareholder Merchants Group still keeps buying on the market, now it controls 10% of the company. Guess Merchants group’s biotech fund may approach few promising pharmaceutical projects, could introduce one to HXL to restart?
meanwhile, HXL’s IP and previous research sounds still have some value, as the company is now under discussion with third party for the opportunity.
short term 1 bagger potential IMV, first SP target is 3.3c -4c easy money.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.171M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| HXL (ASX) Chart |
Day chart unavailable